Edition:
United Kingdom

Novocure Ltd (NVCR.OQ)

NVCR.OQ on NASDAQ Stock Exchange Global Select Market

22.00USD
5:33pm GMT
Change (% chg)

$0.95 (+4.51%)
Prev Close
$21.05
Open
$21.15
Day's High
$22.10
Day's Low
$20.95
Volume
68,257
Avg. Vol
210,834
52-wk High
$24.12
52-wk Low
$6.75

Chart for

About

NovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a cancer treatment centered on a therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Its TTFields delivery system is used for the treatment of glioblastoma (GBM)... (more)

Overall

Beta: --
Market Cap(Mil.): $1,606.50
Shares Outstanding(Mil.): 89.00
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 83.93 16.60
EPS (TTM): -- -- --
ROI: -- 1.66 10.66
ROE: -- 2.58 14.30

BRIEF-Novocure Secures New $150 Mln Non-Dilutive Term Loan Financing

* NOVOCURE SECURES NEW $150 MILLION NON-DILUTIVE TERM LOAN FINANCING

07 Feb 2018

BRIEF-Novocure Announces Q4 And FY17 Operating Statistics And Preliminary Revenue

* NOVOCURE ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 OPERATING STATISTICS AND PRELIMINARY REVENUE

09 Jan 2018

BRIEF-Novocure Receives FDA IDE Approval For Its PANOVA 3 Phase 3 Pivotal Clinical Trial In Advanced Pancreatic Cancer

* NOVOCURE RECEIVES FDA IDE APPROVAL FOR ITS PANOVA 3 PHASE 3 PIVOTAL CLINICAL TRIAL IN ADVANCED PANCREATIC CANCER

18 Dec 2017

BRIEF-Novocure Receives Reimbursement Approval For Optune In Japan For Treatment Of Glioblastoma

* NOVOCURE RECEIVES REIMBURSEMENT APPROVAL FOR OPTUNE® IN JAPAN FOR THE TREATMENT OF NEWLY DIAGNOSED GLIOBLASTOMA

01 Dec 2017

BRIEF-Novocure reports qtrly ‍loss per share $0.13​

* Novocure Ltd - ‍Q3 2017 net revenues of $50.1 million, reflecting 131 percent growth versus Q3 2016​ Source text for Eikon: Further company coverage:

26 Oct 2017

Earnings vs. Estimates